Urolithin A for Stage IV Cancer
Also known as: UA, Mitopure
Mitophagy modulation by urolithin A may enhance anti-tumor immune cell function by maintaining their mitochondrial fitness.
Mechanism of Action
UA improves mitochondrial function in T cells and NK cells, enhancing oxidative phosphorylation needed for sustained anti-tumor activity. It also promotes longevity of memory T cells through mitophagy-dependent metabolic reprogramming.
General mechanism: Gut microbiome metabolite from ellagitannins. PINK1/Parkin mitophagy activator, AMPK activator, mTORC1 inhibitor.
Current Evidence
Preclinical evidence for immune cell metabolic enhancement. Cancer-specific studies emerging. Human muscle aging data informs dosing.
Clinical Status: Preclinical for cancer immune enhancement. Available as supplement.
Safety Profile
Very safe. Naturally derived from pomegranate/ellagitannin metabolism. Well-tolerated in clinical trials.
Key Research Questions
- Does UA improve T cell persistence and anti-tumor activity?
- Can UA enhance immunotherapy response through immune metabolic reprogramming?